title: Endometrial carcinoma: clinical characteristic and survival rates by the new compared to the prior FIGO staging systems.
abstract: OBJECTIVE
  To compare clinical characteristic features and survival rates of endometrial cancer (EMC) patients according to the new 2009 and prior 1988 FIGO staging systems.
  
  
  METHODS
  Clinico-pathological data of EMC patients who had primary surgical treatment between 1992 and 2008 were collected. The new FIGO staging was compared to the prior assigned staging. Survivals of patients according to prior and new staging were compared
  
  
  RESULTS
  Data from 259 patients was reviewed. Mean age was 55.4 +/- 9.9 years. Radiation was the most common adjuvant therapy after surgery, 95/106 patients (89.6%). Progression and recurrences occurred in 34 patients (16 with progression and 18 with recurrence) while 47 died (18.1%). Comparing the prior and current staging, early stage I-II was commonly found in both systems. Stages were the same in 81 patients (31.3%), lower in 177 (68.3%), and higher in one (0.4%). After a median follow-up of 57.5 months, 5-year progression-free, cancer-specific and overall survivals according to the prior and new systems were similar in stage III-IV. Survivals of new stage IA (from 16-prior stage IA, 124-IB, 12-IIA, and 1-IIIA) and stage IB (from 32-IC and 8-IIA) were worse than those of prior stage IA or IB. Survivals of the new stage II patients (11-IIB) were the same as prior stage IIB.
  
  
  CONCLUSIONS
  The "new" FIGO staging system for endometrial cancer patients resulted in lower stage in a large number of patients. Survival trends were worse in the new stage I and remained similar in the other stages.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Vajira Hospital, University of Bangkok Metropolis, Bangkok, Thailand. siriwanonco@yahoo.com
authors.forename: Siriwan
authors.initials: S
authors.lastname: Tangjitgamol
authors.forename: Sunamchok
authors.initials: S
authors.lastname: Srijaipracharoen
authors.forename: Sumonmal
authors.initials: S
authors.lastname: Manusirivithaya
authors.forename: Jakkapan
authors.initials: J
authors.lastname: Khunnarong
authors.forename: Kamol
authors.initials: K
authors.lastname: Pataradool
authors.forename: Thaovalai
authors.initials: T
authors.lastname: Thavaramara
mesh_terms: D000368:Aged; D024221:Antineoplastic Protocols; D017024:Chemotherapy, Adjuvant / Q000379:methods* / Q000706:statistics & numerical data; D002965:Classification / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D004717:Endometrium / Q000473:pathology*; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods* / Q000706:statistics & numerical data; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis; D013785:Thailand / Q000453:epidemiology